Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions.
The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases.
Their novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell’s nucleus with SINE technology (Selective Inhibition of Nuclear Export).
The primary focus is on developing novel drugs which Karopharm hopes will help treat patients with certain blood cancers or solid tumor malignancies.